linjc16/ctgov huggingface dataset:
THRIVE in Pediatric Laryngeal Microsurgery

Study Overview
=================
Brief Summary
-----------------
Transnasal High-flow rapid-insufflation ventilatory exchange (THRIVE) has been shown to benefit oxygenation, ventilation and upper airway patency in a range of clinical scenarios, however its use in spontaneously breathing pediatric patients undergoing tubeless airway surgery has not been described. This is a physiologic study that evaluates the feasibility of THRIVE during pediatric airway surgery under self-respiration.

Official Title
-----------------
The Effects of Transnasal Humidified Rapid Insufflation Ventilator Exchange (THRIVE) on the Oxygenation in Pediatric Patients Under Tubeless Airway Surgery - a Physiologic Study

Conditions
-----------------
Laryngoscopy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pediatric patients undergoing laryngeal microsurgery with spontaneous ventilation Exclusion Criteria: Severe gastrointestinal reflux disease Neuromuscular disease Central hypoventilation

Ages Eligible for Study
-----------------
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| laryngeal microsurgery<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of low saturation events | oxygen saturation decrease lower than 90% | Intraoperative |
Uterine Cavity Volume Measuring With Sonohysterography: A New Objective Method

Study Overview
=================
Brief Summary
-----------------
Measuring of uterine cavity volume using sonohysterography will be done in two groups of patients, Group A included 35 patients for home hysterectomy were indicated and group B includes 150 infertile patients in the childbearing age.

Detailed Description
-----------------
Uterine cavity volume will be measured in group A before and after hysterectomy, and in the group, B will be measured using sonohysterography only using a mathematical method of the sum of a volume of a cone and part of a sphere.

Official Title
-----------------
Uterine Cavity Volume Measuring With Sonohysterography: A New Objective Method

Conditions
-----------------
Cavity

Intervention / Treatment
-----------------
* Diagnostic Test: sonohysterography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients without any gross pathology within the uterus. Patients admitted for hysterectomy. Patients agreed with written consent to participate in the study. Exclusion Criteria: Virgins. Pregnancy. Systemic blood disease. Any clinical evidence of cervical, uterine or tubal infection. Refusal to undergo saline infusion sonography. Any gross uterine pathology diagnosed clinically or with sonography.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group A<br>35 patients with an indication for hysterectomy without gross uterine pathology | Diagnostic Test: sonohysterography<br>* sonohysterography with measuring the uterine cavity volume<br>|
| group B<br>150 infertile patients in the childbearing age without gross uterine pathology | Diagnostic Test: sonohysterography<br>* sonohysterography with measuring the uterine cavity volume<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| calculation of uterine cavity volume with an objective method | measuring uterine cavity volume objectively | one day |
Efficacy Study of the Effect of Budesonide on Emphysema

Study Overview
=================
Brief Summary
-----------------
To assess the effect of up to 4 years treatment with budesonide on progression of emphysema in patients with Chronic Obstructive Lung Disease.

Official Title
-----------------
The Effect of Inhaled Corticosteroids on the Development of Emphysema in Smokers Assessed by Computed Tomography (CT).

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Drug: Pulmicort (budesonide) Turbuhaler


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical Chronic Obstructive Pulmonary Disease diagnosis smoker Exclusion Criteria: No exacerbation within the last 30 days no long term use of oral corticosteroids

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Pulmicort (budesonide) Turbuhaler|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary variable in the study was change in lung density measured by Computed Tomography annually. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decline in lung Function (FEV1) and exacerbation rate were measured biannually and decline in diffusion capacity (TLCO) annually. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Obstructive Pulmonary Disease
Sub-threshold Micro-Pulse Laser Therapy for Drusen of Dry AMD

Study Overview
=================
Brief Summary
-----------------
To investigate the efficacy and safety of sub-threshold micro-pulse laser therapy for drusen of dry age-related macular degeneration (AMD) .

Official Title
-----------------
The Affiliated Eye Hospital of Wenzhou Medical University

Conditions
-----------------
Drusen

Intervention / Treatment
-----------------
* Device: laser treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Older than 50 years of age. Male or female patients with nonexudative AMD with a drusen diameter of at least 125um in the central 3mm circle clear media to perform colour, red-free imaging and fundus fluorescein angiography, fundus autofluorescence imaging and OCT. Able to give an informed consent. Exclusion Criteria: Presence of other macular disease such as epiretinal membrane, macular telangiectasia. unclear media that no clear colour, red-free imaging and fundus fluorescein angiography, fundus autofluorescence imaging and OCT can performed. Ocular or periocular infections.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Laser<br> | Device: laser treatment<br>* sub-threshold micro-pulse laser treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in macular drusen volume | Mean change in macular drusen volume on optical coherence tomograph(OCT) | 6 and 12 months | 
| Change in macular drusen area | Mean change in macular drusen area on OCT | 6 and 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in visual acuity | Mean change in best-corrected visual acuity | 6 and 12 months |
Comparison of Colonoscopy and Sigmoidoscopy in Terms of Pain, Acceptance and Procedure Time

Study Overview
=================
Brief Summary
-----------------
According to experience in a self-payed health check-up center,unsedated total colonoscopy is not inferior or may be better than unsedated sigmoidoscopy in terms of pain and patients' acceptance. Hypothesis: Unsedated total colonoscopy is not inferior to unsedated sigmoidoscopy in terms of pain and patients' acceptance.

Detailed Description
-----------------
According to American Cancer Society guideline, screening total colonoscopy every 10 years or sigmoidoscopy every 5 years is recommended for average risk people above 50 years old. However,study in Taiwanese population demonstrated that 37.8% of colorectal lesions were beyond reach of sigmoidoscope, and in cases with lesions with advanced pathology, 66.7% did not have distal colorectal lesion. However, many people think colonoscopy is more painful and choose sigmoidoscopy for screening. However, according to experience in a self-payed health check-up center,unsedated total colonoscopy is not inferior or may be better than unsedated sigmoidoscopy in terms of pain and patients' acceptance.

Official Title
-----------------
Comparison of Colonoscopy and Sigmoidoscopy in Terms of Pain, Acceptance and Procedure Time

Conditions
-----------------
Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who undergo self-payed unsedated colonoscopy or sigmoidoscopy for colon cancer screening. Exclusion Criteria: Difficulty in assessing pain during the procedure and acceptance for the procedure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colonoscopy, Sigmoidoscopy, Colon cancer screening, Pain, Screening
To Validate the Specific Patterns of Magnetocardiography, a Non-invasive Non-contact Examination for Patients With Ischemic Heart Disease or Cardiac Arrhythmia

Study Overview
=================
Brief Summary
-----------------
ECG is one of the most important non-invasive method to diagnose CAD and arrhythmia. However, clinically it still has its limitation. Because the electrical field could induce a magnetic field, the newly developed non-contact technique, magnetocardiography, was established to detect the local magnetic field component of the heart. It is safe and more convenient. In this study, we try to define and validate the magnetocardiographic patterns in the patients with cardiac arrhythmias or ischemia.

Official Title
-----------------
To Validate the Specific Patterns of Magnetocardiography, a Non-invasive Non-contact Examination for Patients With Ischemic Heart Disease or Cardiac Arrhythmia

Conditions
-----------------
Arrhythmia

Intervention / Treatment
-----------------
* Other: MCG


Participation Criteria
=================
Eligibility Criteria
-----------------
Patient enrollment: patients older than 18 years old, having received 1) 12-lead ECG examination for suspected cardiac arrhythmias or 2) stress tests for suspected coronary artery disease, will be invited. The patients who have medical devices made of metallic or magnetic material (ex. pacemaker, mechanical valve and arthroplasty) will be excluded to prevent the experimental bias.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: MCG|Cardiac Arrhythmia,Heart Disease|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diagnose cardiac arrhythmia and CAD., we'll try to establish the specific model to detect and diagnose cardiac arrhythmia and CAD.
Follicular Helper T Cells: Biological Marker and Involvement in the Physiopathology of the IgG4-related Disease

Study Overview
=================
Brief Summary
-----------------
IgG4-related disease is a rare and very recently identified pathology, whose frequency is certainly underestimated. The clinical presentation varies among affected organs, and most often, patients have at least three organ damage. These organs exhibit tissue infiltration mononuclear polymorphic cells with often severe fibrosis progression resulting in a loss of function. The biomarker, though not specific, is a polyclonal elevated serum IgG4, and histological marker, currently held by several teams, is the presence within the inflammatory infiltrate, of a predominance of IgG4-expressing plasma-cells with a relative plasma-cells IgG4 + / IgG +> 50% on tissue immunostaining. The investigators project provides a global assessment of T lymphocyte abnormalities and specifically the TFH (Follicular Helper) during this IgG4-related disease compared to so-called groups control subjects suffering from Sjogren syndrome or healthy subjects.

Official Title
-----------------
Follicular Helper T Cells: Biological Marker and Involvement in the Physiopathology of the IgG4-related Disease

Conditions
-----------------
IgG4-related Disease

Intervention / Treatment
-----------------
* Biological: extra blood draw samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: IgG4-related disease patients or Sjogren syndrome patients or Healthy subjects Exclusion Criteria: Presence of autoimmune or inflammatory associated disease Age less than 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IgG4-related disease<br>Subjects suffering from IgG4-related disease | Biological: extra blood draw samples<br> <br> |
| Active Comparator: Sjögren syndrome<br>Subjects suffering from Sjôgren syndrome | Biological: extra blood draw samples<br> <br> |
| Active Comparator: Healthy controls<br>Healthy subjects | Biological: extra blood draw samples<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of Follicular Helper T cells (CD4 + CXCR5 + ICOShigh) in the blood |  | 36 months |
A Single-dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500mg Tablets Under Fasting Conditions

Study Overview
=================
Brief Summary
-----------------
A single-dose, comparative bioavailability study of two formulations of ursodiol 500mg tablets under fasting conditions

Detailed Description
-----------------
A single-dose, comparative bioavailability study of two formulations of ursodiol 500mg tablets under fasting conditions: open label, single-dose, randomized, two-period, two-treatment, two-sequence, crossover, comparative bioavailability study

Official Title
-----------------
A Single-dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500mg Tablets Under Fasting Conditions

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Ursodiol 500 MG
* Drug: Urso Forte 500Mg Tablet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy, non-smoking, male and female subjects, 18 years of age or older BMI ≥ 19.0 and ≤ 30.0 kg/m2. Females who participate in this study will be of chilbearing or non-childbearing potential Exclusion Criteria: • Know history or presence of clinically significant neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the investigator, would jeopardized the safety of the subject or impact the validity of the study results

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ursodiol 500mg tablets<br>Ursodiol 500mg tablets followed by Urso Forte 500mg tablets | Drug: Ursodiol 500 MG<br>* Ursodiol 500mg tablets followed by Urso Forte 500mg tablets<br>|
| Active Comparator: Urso Forte 500mg tablets<br>Urso forte 500mg tablets followed by Ursodiol 500mg tablets | Drug: Urso Forte 500Mg Tablet<br>* Urso forte 500mg tablets followed by Ursodiol 500mg tablets<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum Plasma Concentration (Cmax) |  | 0-72 hours | 
| Area under the plasma concentration versus time curve (AUC) |  | 0-72 hours |
Analysis of Immunological Reactions to Foods in Birch Pollen-Allergic Patients

Study Overview
=================
Brief Summary
-----------------
A high number of birch pollen-allergic individuals develop hypersensitivity reactions to certain foods, e.g. apples. This food allergy is due to immunological cross-reactivity. Birch pollen-related foods contain proteins, e.g. Mal d 1 in apple, that are structurally related with the major birch pollen allergen, Bet v 1. Hence IgE antibodies and T lymphocytes specific for Bet v 1 recognize these food proteins which results in activation of the immune system and, consequently, in clinical symptoms. In the present study the investigators intend to investigate if and how the consumption of birch pollen-related food allergens affects birch pollen allergy. In other words, the investigators are interested to analyse whether Bet v 1-related food allergens activate Bet v 1-specific memory cells and thus, contribute to the maintenance of the pollen allergy outside the pollen season. Data obtained in this study will help to clarify the immunological and clinical role of cross-reactivity between pollen and food allergies and will reveal whether avoidance of such foods should be recommended for the patients. Finally, novel approaches for diagnosis and therapy of pollen-related food allergens can be developed.

Official Title
-----------------
Analysis of Immunological Reactions to Pollen-Related Foods in Birch Pollen-Allergic Patients

Conditions
-----------------
Allergic Rhinitis, Food Allergy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Otherwise healthy birch pollen allergic (rhinoconjunctivitis)persons Positive SPT and RAST to birch pollen Sensitized to Bet v 1 Exclusion Criteria: Persons suffering from malignancies, autoimmune and cardiopulmonary diseases Anemia Hyper-IgE syndrome Treatment with ß-blockers, permanent treatment with antihistaminics, leucotriene antagonists, corticosteroids

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
birch pollen pollen allergy, oral allergy syndrome to apple, cross reactivity, bet v 1, mal d 1
Iron Interventions and Non-transferrin-bound Iron (NTBI) in Women

Study Overview
=================
Brief Summary
-----------------
The overall goal of this research is to develop safe and effective iron interventions that can be administered without production of plasma non-transferrin-bound iron (NTBI: iron in the systemic circulation not bound to the iron-transport protein transferrin). The appearance of plasma non-transferrin-bound iron has been reported in uninfected adult volunteers after oral administration of iron supplements in doses similar to those used in the Pemba trial. This research project will (i) confirm the appearance of plasma non-transferrin-bound iron after administration of an iron supplement like that in the Pemba trial ( 1 mg Fe/kg body weight, without food), and then determine the effects on production of plasma non-transferrin-bound iron and on iron absorption measured with stable isotopes (ii) of giving the supplemental iron ( 1 mg Fe/kg) with the standard rice meal, and (iii) of giving a lower dose of iron ( 0.1 mg Fe/kg) - like that used in home fortification - with the standard rice meal.

Official Title
-----------------
The Influence of Iron Interventions on Formation of Non-transferrin-bound Iron (NTBI) in Women

Conditions
-----------------
Iron Deficiency

Intervention / Treatment
-----------------
* Dietary Supplement: Ferrous sulfate
* Dietary Supplement: Ferrous sulfate
* Dietary Supplement: Ferrous sulfate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: non pregnant non lactating apparently healthy women Exclusion Criteria: chronic disease pregnancy lactation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Iron supplement without food<br> | Dietary Supplement: Ferrous sulfate<br>* 60 mg Ferrous sulfate<br>|
| Experimental: Iron supplement with food<br> | Dietary Supplement: Ferrous sulfate<br>* 60 mg ferrous sulfate<br>|
| Experimental: Iron fortificant with food<br> | Dietary Supplement: Ferrous sulfate<br>* 6 mg ferrous sulfate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Formation of NTBI following oral iron administration |  | 6 time points within 8 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum iron isotope appearance curves |  | 6 time points within 8 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NTBI, Iron, Absorption